{
    "clinical_study": {
        "@rank": "134577", 
        "arm_group": {
            "arm_group_label": "DCE-MRI and DWI", 
            "arm_group_type": "Experimental", 
            "description": "Single arm study, diagnosis defined as BIRADS 3, 4, or 5 lesion(s) based on DCE-MRI only with DWI collected in tandem as standard practice."
        }, 
        "brief_summary": {
            "textblock": "A type of magnetic resonance imaging called diffusion weighted imaging (DWI) will be tested\n      to define cancerous from non-cancerous lesions in the breast."
        }, 
        "brief_title": "DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "BIRADS 3", 
            "BIRADS 4", 
            "BIRADS 5"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "For this study, the investigators plan to evaluate DWI scans performed in women with breast\n      lesions identified by conventional breast MRI. The investigators will determine whether an\n      ADC threshold can be defined for distinguishing benign and malignant lesions on DWI, assess\n      the difference in ADC cutoffs for mass and non-mass lesions, and investigate the potential\n      improvement in accuracy using techniques such as nonzero minimum b-value (to remove\n      perfusion effects in the ADC measures) and normalized ADC measures (to account for\n      variations in water content and other factors)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide written informed consent;\n\n          -  18 years of age or older;\n\n          -  Successful completion of breast MR examination with DWI required by protocol;\n\n          -  Undiagnosed breast lesion (BI-RADS 3, 4, or 5) identified on MRI. The BI-RADS\n             assessment must refer to a focal finding within the breast (i.e. mass, non-mass, or\n             focus) as opposed to diffuse processes (e.g. background parenchymal enhancement, skin\n             thickening) or lesions outside the subcutaneous breast (e.g. axillary lymph nodes,\n             focal skin lesions, osseous lesions, etc.).\n\n        Exclusion Criteria:\n\n          -  Participants with current or recent history (within 6 months prior to the MRI) of\n             chemotherapy for cancer;\n\n          -  Neoadjuvant chemotherapy between MRI and confirmation of lesion outcome (study\n             lesions must be biopsied prior to undergoing any chemotherapy);\n\n          -  Pregnant (if a female is of childbearing potential - defined as a pre-menopausal\n             female capable of becoming pregnant - confirmation of pregnancy status per the site's\n             standard of practice should be done prior to MRI);\n\n          -  Unwilling or not suitable to undergo MRI or use the contrast agent gadolinium."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022579", 
            "org_study_id": "ACRIN 6702"
        }, 
        "intervention": {
            "arm_group_label": "DCE-MRI and DWI", 
            "description": "DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up", 
            "intervention_name": "DCE-MRI and DWI", 
            "intervention_type": "Procedure", 
            "other_name": [
                "magnetic resonance imaging", 
                "MRI", 
                "DCE-MRI", 
                "DWI", 
                "DW-MRI"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Cancer", 
            "Diagnosis", 
            "Malignant", 
            "Benign", 
            "Biopsy"
        ], 
        "lastchanged_date": "February 21, 2014", 
        "link": {
            "description": "For additional information on the ACRIN 6702 trial, visit ACRIN.ORG.", 
            "url": "http://www.acrin.org"
        }, 
        "location": {
            "contact": {
                "email": "drguay@uw.edu", 
                "last_name": "Diane Guay", 
                "phone": "206-598-9322"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "University of Washington"
            }, 
            "investigator": {
                "last_name": "Savannah Partridge, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A MULTI-CENTER STUDY EVALUATING THE UTILITY OF DIFFUSION WEIGHTED IMAGING FOR DETECTION AND DIAGNOSIS OF BREAST CANCER", 
        "overall_contact": {
            "email": "scp3@u.washington.edu", 
            "last_name": "Savannah Partridge, PhD", 
            "phone": "206-288-1306"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Washington", 
                "last_name": "Savannah Partridge, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Washington", 
                "last_name": "Habib Rahbar, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Michigan", 
                "last_name": "Thomas Chenevert, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: National Cancer Institutes", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Whether the Apparent Diffusion Coefficient (ADC), when used systematically in conjunction with conventional Dynamic Contrast Enhanced-Magnetic Resonance Imaging (DCE-MRI), can reduce the biopsy rate by at least 20% while maintaining sensitivity.", 
            "measure": "Apparent Diffusion Coefficient (ADC)", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Whether optimal ADC cutoffs are different for mass and non-mass lesion types;", 
                "measure": "Optimal ADC Cutoffs by Lesion Type", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Whether site-generated ADC values differ significantly from those obtained by central review;", 
                "measure": "Local and Central Review Comparison (ADC Value Differences)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Whether the use of a nonzero minimum b-value to reduce perfusion effects in ADC calculation can increase the area under the curve (AUC) for differentiating benign and malignant lesions;", 
                "measure": "Minimum B-Value for Differentiating Lesions", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Whether the use of a normalized ADC measure (tumor/normal ratio) to account for inter- and intra-subject variations in water content and other factors can increase the AUC for differentiating benign and malignant lesions;", 
                "measure": "ADC Measurements/Ratios to Define Subject Lesion Variations", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Whether ADC with nonzero minimum b-value and/or normalized ADC can reduce the biopsy rate while maintaining sensitivity.", 
                "measure": "Combination Variables (ADC Nonzero Minimum B-Value and/or Normalized ADC)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "American College of Radiology Imaging Network", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institutes", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "ECOG", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "American College of Radiology Imaging Network", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}